Literature DB >> 12560048

Determination of 3'-C-ethynylcytidine in human plasma and urine by liquid chromatographic-electrospray ionization tandem mass spectrometry.

Kazuaki Matsuoka1, Ryuichi Kitamura, Eiji Matsushima, Yasuro Kawaguchi.   

Abstract

A liquid chromatographic-electrospray ionization tandem mass spectrometric (LC-ESI/MS/MS) method was developed for the quantitative analysis of a novel anticancer drug, 3'-C-ethynylcytidine (I) in human plasma and urine. I and its stable isotope-labeled internal standard (II) were extracted from human plasma and urine samples using a polymer-based cation-exchange cartridge, and LC-ESI/MS/MS analysis was performed by monitoring the positive fragment ions of I and II. The linear ranges are 1-500 ng/ml in plasma and 10-5000 ng/ml in urine. The limits of quantitation for I were 1 ng/ml in plasma and 10 ng/ml in urine. The relative errors (RE) for I ranged from -8.4 to 3.0% in plasma and from 0.8 to 4.4% in urine. The relative standard deviations (RSD) for I ranged from 1.2 to 8.9% in plasma and from 0.7 to 2.8% in urine. This validated analytical method is demonstrated to be useful for the analysis of I in human plasma and urine in clinical studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12560048     DOI: 10.1016/s0731-7085(02)00607-6

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  1 in total

1.  Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.

Authors:  Lisa A Hammond-Thelin; Melanie B Thomas; Michiko Iwasaki; James L Abbruzzese; Yvonne Lassere; Christina A Meyers; Paulo Hoff; Johann de Bono; Jody Norris; Hitoshi Matsushita; Akira Mita; Eric K Rowinsky
Journal:  Invest New Drugs       Date:  2010-09-14       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.